The GALAD score performs better than AFP in hepatocellular carcinoma screening: a single-centre, case-control study in Malaysia
GALAD outperformed conventional biomarkers, facilitating early detection, improved treatment options and ultimately a higher survival rate for HCC patients.
Authors
- Khairul Najmi Muhammad Nawawi (ORCID: https://orcid.org/0000-0002-5309-5301)
- Zulhabri Othman (ORCID: https://orcid.org/0000-0003-3837-9602)
- Wei Hao Kok
- Munirah Md Mansor (ORCID: https://orcid.org/0000-0002-6500-7823)
- Zhiqin Wong (ORCID: https://orcid.org/0000-0002-9060-8348)
- Wai Lok Woo (ORCID: https://orcid.org/0000-0002-8698-7605)
- Deborah Chia Hsin Chew
- Azlanudin Azman (ORCID: https://orcid.org/0000-0002-5897-3134)
- Raja Affendi Raja Ali
- Nur Yazmin Yaacob
Institutions
- Hospital Kuala Lumpur (MY)
- University Kebangsaan Malaysia Medical Centre (MY)
- Sunway University (MY)
- National University of Malaysia (MY)
Publication Details
- Journal
- Clinical and Experimental Hepatology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/ceh.2025.148321
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00